Ann Arbor Stage III Diffuse Large B-Cell Lymphoma
6 clinical trials · Condition
◉ Watch Ann Arbor Stage III Diffuse Large B-Cell Lymphoma
| Record | Firm | Date |
|---|---|---|
| A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma (NCT04139304) | AIDS Malignancy Consortium | 2021-05-24 |
| Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma (NCT04799275) | National Cancer Institute (NCI) | 2021-05-20 |
| Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma (NCT04323956) | Mayo Clinic | 2020-06-15 |
| Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas (NCT03220022) | National Cancer Institute (NCI) | 2018-03-16 |
| Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas (NCT01193842) | National Cancer Institute (NCI) | 2010-10-06 |
Track Ann Arbor Stage III Diffuse Large B-Cell Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.